Friulimicin B is a naturally occurring antibiotic produced by a micro-organism, Actinoplanes friuliensis. It shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in...
- Mechanism
- Curator reviewed
Friulimicin B, in the presence of calcium, forms a complex with a lipid carrier that acts in cell wall biosynthesis and which is not targeted by other antibiotics currently in use. Friulimicin B appears to block two essential pathways in the cell envelope and the complexes formed prevent the formation of a functional cell wall.
- Primary indication
- Investigated for use/treatment in bacterial infection.Curator reviewed
- Formula / weight
- C59H94N14O19 · 1303.48 g/mol (avg)
- Also known as
- Friulimycin B
- Code names
- A 1437 delta
Resolves to
HVYFVLAUKMGKHL-USKUEUQVSA-NSMILESCC(C)CCCCCCC\C=C/CC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]1[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H]2CCCCN2C1=O)[C@H](C)C(O)=O)[C@@H](C)N)C(C)CWhat you can answer from here — as of June 12, 2020
Which companies are running trials of Friulimicin B, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account